Journal of Medicinal Chemistry · 2020 · 77 citations · 53 references
PharmacyChemistryMedicinal ChemistryDrug DesignDrug DiscoveryLead OptimizationFragment-based Drug DesignFragment-based Lead DiscoveryFragment-based OptimizationHit-to-lead OptimizationLead DiscoveryLigand Efficiency OptimizationFragment OptimizationFragment-based DiscoveryFragment-based Lead DesignFragment-based Lead OptimizationFragment-based Ligand DesignLead ChemistryMedicinal Chemistry ApplicationsPhysicochemical Properties
This Perspective, the fourth in an annual series, summarizes fragment-to-lead (F2L) success stories published during 2018. Topics such as target class, screening methods, physicochemical properties, and ligand efficiency are discussed for the 2018 examples as well as for the combined 111 F2L examples covering 2015-2018. While the overall properties of fragments and leads have remained constant, a number of new trends are noted, for example, broadening of target class coverage and application of FBDD to covalent inhibitors. Moreover, several studies make use of fragment hits that were previously described in the literature, illustrating that fragments are versatile starting points that can be optimized to structurally diverse leads. By focusing on success stories, the hope is that this Perspective will identify and inform best practices in fragment-based drug discovery.
53
Ligand and Target Discovery by Fragment-Based Screening in Human Cells
Christopher G. Parker, Andrea Galmozzi, Yujia Wang et al. · Cell · 2017 · 462 citations · Full text
Thomas Ryckmans, Martin P. Edwards, Val A. Horne et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 269 citations · Full text
Siegfried Reich, Paul A. Sprengeler, Gary G. Chiang et al. · Journal of Medicinal Chemistry · 2018 · 177 citations · Full text